TrkA 1-3S4R-4-3--1-2--3--3-4--3-2--5--1--1H--5-1-3S4R-4-3-FLUOROPHENYL-1-2-METHOXYETHYLPYRROLIDIN-3-YL-3-4-METHYL-3-2-METHYLPYRIMIDIN-5-YL-1-PHENYL-1H-PYRAZOL-5-YLUREA AS A TRKA KINASE INHIBITOR

• Main Authors: ALLEN SHELLEY, ANDREWS STEVEN W, CRANE ZACKARY, BAER BRIAN, WATSON DANIEL JOHN, LIU WEIDONG
• Format: Patent
• Language: English; Korean
• Published: 16.01.2017
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

TrkA 키나제의 저해제이고 TrkA 키나제 저해제로 치료될 수 있는 질환, 예컨대, 통증, 암, 염증 및 염증성 질환, 신경변성 질환, 소정의 감염성 질환, 쇼그렌 증후군, 자궁내막증, 당뇨병성 말초 신경병증, 전립선염, 골반 통증 증후군, 골 리모델링의 조절의 불균형과 관련된 질환, 및 결합조직 성장인자 이상 신호전달에 기인된 질환의 치료에 유용한, 하기 화합물(I) 또는 이의 약제학적으로 허용 가능한 염이 제공된다:. Provided is Compound 1or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling.